Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other financing activities (2021 - 2025)

Lyra Therapeutics has reported Other financing activities over the past 5 years, most recently at $368000.0 for Q3 2025.

  • Quarterly results put Other financing activities at $368000.0 for Q3 2025, up 1500.0% from a year ago — trailing twelve months through Dec 2025 was $391000.0 (up 34.83% YoY), and the annual figure for FY2025 was $726000.0, up 150.34%.
  • Other financing activities for Q3 2025 was $368000.0 at Lyra Therapeutics, up from $23000.0 in the prior quarter.
  • Over the last five years, Other financing activities for LYRA hit a ceiling of $4.0 million in Q2 2022 and a floor of $2000.0 in Q1 2022.
  • Median Other financing activities over the past 5 years was $169000.0 (2024), compared with a mean of $522272.7.
  • Biggest five-year swings in Other financing activities: plummeted 94.52% in 2024 and later soared 1500.0% in 2025.
  • Lyra Therapeutics' Other financing activities stood at $4000.0 in 2021, then surged by 5800.0% to $236000.0 in 2022, then soared by 36.44% to $322000.0 in 2023, then tumbled by 92.86% to $23000.0 in 2024, then soared by 1500.0% to $368000.0 in 2025.
  • The last three reported values for Other financing activities were $368000.0 (Q3 2025), $23000.0 (Q3 2024), and $98000.0 (Q2 2024) per Business Quant data.